Cellvax
Romainville, FR· latest recorded location
Cellvax is named on 2 US grants and 2 published applications in this corpus. Its most frequent classification is A61K (Medicines and medical preparations).
- Granted patents
- 2
- Published applications
- 2
- Inventors
- 7
- Granted in 2026 so far
- 1
- Most recent grant
- 6 Jan 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2017 | 0 | 1 |
| 2018 | 0 | 0 |
| 2019 | 0 | 0 |
| 2020 | 0 | 0 |
| 2021 | 1 | 1 |
| 2022 | 0 | 0 |
| 2023 | 0 | 0 |
| 2024 | 0 | 0 |
| 2025 | 0 | 0 |
| 2026 | 1 | 0 |
By publication year. 2026 runs to 8 Oct.
Technology areas
Share of 4 documents
Recent patents
- Antibody which is directed against galectin-9 and is an inhibitor of the suppressor activity of regulatory T lymphocytes6 Jan 2026US 12,516,125 B2
- Antibody which is directed against galectin-9 and is an inhibitor of the suppressor activity of regulatory T lymphocytes26 Jan 2021US 10,899,838 B2
- Antibody which is Directed Against Galectin-9 and is an Inhibitor of the Suppressor Activity of Regulatory T Lymphocytes15 Apr 2021US 2021/0107984 A1
- Antibody which is directed against galectin-9 and is an inhibitor of the suppressor activity of regulatory t lymphocytes5 Oct 2017US 2017/0283499 A1
Most cited
By later US patents